Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

0.00%

$1.75 viralytics limited

Did they talk about speeding up recruitment? That is something...

First 9 Last

Share
Profile

Follow
hotcongo

3,781 Posts.

630

23/11/16

17:20

Post #: 20831558
Share

Originally posted by DavieJones ↑

I attended also & agree with all of the feedback above. Thanks guys. I hope it is the last AGM via a buyout in the next 12 months !

The VLA directors weren't being cagey when they were discussing future plans. The way forward is to keep progressing with trials until a commercial partnering/licencing/sale offer comes along that exceeds expectations, which is out of their control. So they have to keep generating data, and the ultimate shareholder value increases with each positive result. Once the data set is complete (whenever that is), VLA can progress with the "auction" with interested parties.

Just a comment on the virus types... Malcolm mentioned that viruses such as T-Vec that have been genetically-engineered tend to lose their viralency or activity versus wild-types such as Cavatak. Also, Darren mentioned that Cavatak is an RNA based virus which is much more viralent compared with the DNA based viruses (nearly all of the competition including T-Vec) which are much less viralent/active.

Also on the manufacturing side, the current contract manufacturer in USA can easily scale up production to meet future demand. Not a worry there.

Hope this helps.

.

Expand

Did they talk about speeding up recruitment? That is something presumably under their control and would hasten the release of more good data. Part of trial execution success is executing quickly, rather than having trials drag out.

As a previous poster said, perhaps VLA's low side-effects track record will allow recruitment to happen a lot faster now...

VLA Price at posting: $1.18 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil